Price T Rowe Associates Inc Atreca, Inc. Transaction History

Price T Rowe Associates Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.87 - $6.29 $52,044 - $114,062	-18,134 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $33,879 - $62,583	6,900 Added 61.42%	18,134 $113,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $3,260 - $5,754	417 Added 3.86%	11,234 $96,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $962 - $1,431	74 Added 0.69%	10,817 $166,000
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $139,981 - $183,597	10,743 New	10,743 $173,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.